Mereo BioPharma Group plc Balance Sheet
MREO|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Mereo BioPharma Group plc had $46M in total assets and $41M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $41.0M | $69.8M | $57.4M |
| Current Assets | $45.0M | $74.8M | $63.8M |
| PP&E (Net) | $137.0K | $257.0K | $405.0K |
| Total Assets | $45.9M | $76.4M | $66.5M |
| Current Liabilities | $4.3M | $13.8M | $9.5M |
| Shareholders' Equity | $40.9M | $61.0M | $50.5M |